BMS Offers Deep Discounts on Deucravacitinib (Sotyktu)
Bristol Myers Squibb (BMS) is expanding its direct-to-patient offerings, providing eligible U.S. patients with steeply discounted prices for deucravacitinib (Sotyktu) and apixaban (Eliquis).
Category: Psoriasis